Fact-checked by Grok 2 weeks ago

Jonathan Rothberg

Jonathan Rothberg is an biochemist, inventor, and serial entrepreneur renowned for pioneering next-generation technologies and founding multiple and companies. Born in 1963 in , to a family of entrepreneurs, Rothberg earned a B.S. in from and an M.S., M.Phil., and Ph.D. in from . Rothberg's career began with the founding of CuraGen Corporation in 1991, a company that reached a valuation of $5 billion by 1999 through its work in and . In 2000, he established 454 Life Sciences, where he invented high-throughput, massively parallel , marking the first major advancement in sequencing since the Sanger method and enabling the $1,000 milestone. This technology facilitated the sequencing of the first individual , that of , in 2007. Rothberg later founded Ion Torrent in 2007, introducing semiconductor chip-based sequencing that revolutionized accessibility and speed in genetic analysis. Expanding into medical devices, Rothberg co-founded in 2011, developing the Butterfly iQ, a handheld device that connects to smartphones for portable imaging, which earned the Best Medical Technology award in 2024. He has also launched other ventures through his incubator 4Catalyzer, founded in 2014, including for single-molecule , Hyperfine for portable MRI systems, Detect for at-home , and Identifeye Health for AI-driven screening. With over 400 patents to his name, Rothberg's innovations have accelerated advancements in , diagnostics, and . In recognition of his contributions, Rothberg received the 2015 National Medal of Technology and Innovation, presented by President , for "pioneering inventions and commercialization of next-generation technologies." He has been honored as a Technology Pioneer multiple times, Entrepreneur of the Year in , and inducted into the Florida Inventors Hall of Fame in 2023. Rothberg continues to lead as chairman and founder of 4Catalyzer, driving innovation in health technologies with a team exceeding 500 members and over $2 billion in funding.

Early life and education

Early life

Jonathan Rothberg was born in 1963 in , the second-youngest of seven siblings. His parents, Henry and Lillian Rothberg, co-founded Laticrete International, Inc., a specializing in innovative construction materials such as ceramic tile adhesives, which exposed him to from a young age as he frequently accompanied his father on sales calls. The Rothberg family exhibited strong scientific inclinations that profoundly shaped his interests; his father, a , converted the basement of their home into a , fostering an environment where dinner table conversations revolved around and , inspiring Rothberg's future pursuits in these fields.

Education

Rothberg earned a degree in from in 1985. He then pursued advanced studies in biology at Yale University, where he obtained a Master of Science, a Master of Philosophy, and a Doctor of Philosophy degree, completing his PhD in 1991. During his graduate work at Yale, Rothberg's research centered on molecular biology, with his doctoral thesis focusing on the identification and sequencing of the slit gene in Drosophila melanogaster, which encodes a protein critical for axon guidance and neural wiring in the developing nervous system. This early work on gene decoding introduced him to the challenges and potential of genomic sequencing technologies, sparking his enduring interest in genomics.

Scientific contributions

Next-generation DNA sequencing

Jonathan Rothberg pioneered next-generation through his founding of 454 Life Sciences in 2000, where he developed the first commercial sequencing platform based on . This method involves real-time detection of release during , achieved by incorporating into a growing strand and measuring the resulting light emission via enzyme activity, enabling high-throughput sequencing in microfabricated picoliter-volume reactors containing millions of DNA beads. The Genome Sequencer GS 20, launched in 2005, marked the debut of this technology, generating up to 200,000 reads per run and dramatically reducing sequencing time and cost compared to traditional Sanger methods. A landmark application of this technology was the sequencing of James D. Watson's genome in 2007, the first individual human genome sequenced using next-generation methods rather than . Rothberg led the effort at 454 Life Sciences, producing 106.5 million high-quality reads with the Genome Sequencer FLX instrument, achieving 7.4-fold coverage of the diploid genome in just two months at a cost under $1 million, and identifying over 3 million single nucleotide polymorphisms (SNPs). Published in in 2008, this achievement demonstrated the platform's scalability for and paved the way for affordable whole-genome sequencing. Rothberg's innovations in sequencing technologies are protected by over 100 patents, including key ones like US Patent 7,244,567 for double-ended sequencing methods that enhanced read accuracy and length. These patents cover aspects of bead-based emulsion amplification and parallelized detection systems central to 454's approach. The broader implications of Rothberg's work have accelerated research by democratizing access to high-throughput sequencing, allowing individual labs to generate volumes previously reserved for large consortia. This has expanded applications in , structural variation analysis, and discovery, fostering advancements in and enabling the first de novo assemblies of complex genomes without reference sequences.

Other biomedical innovations

Rothberg's innovations extend beyond into diagnostics and imaging, leveraging and microfluidic technologies to enhance accessibility and precision in biomedical applications. At CuraGen, Rothberg advanced the use of industrial-scale for , employing differential techniques such as GeneCalling and to identify novel therapeutic targets in cardiovascular diseases. These methods analyzed thousands of gene fragments from disease models, revealing differentially expressed genes like and TGFβ, which informed pharmacogenomic strategies for assessing drug efficacy and toxicity. In the realm of nucleic acid analysis, Rothberg contributed to the development of droplet-based digital through his work at RainDance Technologies, where he co-authored research on high-throughput quantitative in picoliter droplets. This approach encapsulates reactions in millions of oil-emulsified droplets on a microfluidic chip, enabling rapid cycling—completing 35 cycles in 35 minutes—and sensitive detection of low template concentrations as low as 0.003 pg/μL, aligning with for absolute quantification without standards. Rothberg pioneered single-molecule as a founder of Quantum-Si, co-authoring a seminal that uses an integrated for real-time analysis. The technique employs dye-labeled recognizers and aminopeptidases to sequentially cleave and identify N-terminal residues via fluorescence intensity, lifetime, and binding kinetics, achieving single-molecule sensitivity to discriminate substitutions and posttranslational modifications for proteomic research and . Rothberg's work in includes the creation of portable technology at , where he co-developed the iQ system—a handheld, whole-body probe based on a chip with a single piezoelectric micromachined array. This innovation replaces traditional multi-probe cart-based systems with a smartphone-compatible device, democratizing point-of-care imaging by reducing size, cost, and complexity while maintaining diagnostic resolution. Similarly, at Hyperfine, Rothberg led the invention of the Swoop portable MRI system, a low-field (0.064 ) device that weighs under 2,000 pounds and operates on standard power outlets, consuming 35 times less energy than conventional 1.5 scanners. By adapting permanent magnet and deep-learning reconstruction techniques, it enables bedside brain imaging without shielding, aiming to expand MRI access in resource-limited settings.

Business career

CuraGen

CuraGen Corporation was founded by Jonathan Rothberg in 1991 while he was a graduate student at , marking it as one of the earliest companies dedicated to . Drawing briefly from his PhD work on expressed sequence tags, Rothberg steered the company toward applying genomic technologies to biological discovery. The firm specialized in and to identify disease-related genes and proteins, enabling partnerships with pharmaceutical companies for accelerated and development. CuraGen's platforms, such as PathCalling for dynamic pathway analysis, supported collaborations with major players like and to validate therapeutic targets. CuraGen went public through an on (ticker: CRGN) in September 1999, raising approximately $40 million, and achieved a peak of about $5 billion by 2000 amid the boom. Rothberg served as the company's Chairman and from its until his resignation in April 2005, after which he transitioned to focus on other ventures. Despite early successes, CuraGen faced mounting financial pressures from high research costs and a cooling biotech market, leading to workforce reductions and pipeline shifts in the mid-2000s. In 2009, the company merged with Celldex Therapeutics in a $94.5 million stock-for-stock deal, becoming a wholly-owned subsidiary and effectively dissolving its independent operations while contributing its portfolio to Celldex's efforts.

454 Life Sciences

454 Life Sciences was founded in 2000 by Jonathan Rothberg as a from his earlier company, CuraGen Corporation, with the goal of advancing genome sequencing technologies. The company developed pyrosequencing-based instruments, culminating in the launch of the Genome Sequencer 20 (GS 20) in October 2005, which became the first commercially available next-generation DNA sequencer on the market. This instrument enabled the production of approximately 20 million bases per run, marking a significant step toward scalable genomic analysis. In March 2007, Roche Diagnostics acquired 454 Life Sciences from CuraGen for $140 million in cash, with potential additional payments bringing the total to $154.9 million. Following the acquisition, 454 continued operations as a , contributing to advancements in sequencing applications until Roche initiated its closure in October 2013. 454 Life Sciences played a pivotal role in enabling affordable, high-throughput sequencing by commercializing parallelized , which reduced costs and increased speed compared to traditional methods. Sequencing innovations, including bead-based and parallel readout, were prototyped and refined at the company.

RainDance Technologies

In 2004, Jonathan Rothberg founded RainDance Technologies, Inc., a company specializing in to advance and analysis in . Rothberg served as the company's Chairman and from its inception until 2009, guiding its focus on innovative tools for handling and detection. RainDance Technologies developed the RainDrop Digital system, a that employs picodroplet technology to partition samples into over a million individual reaction volumes, enabling absolute and precise quantification of s without the need for standard curves. This system supports multiplexed assays and offers ultrasensitive detection, capable of identifying rare targets at frequencies as low as 1 in 250,000 molecules. By leveraging probe-based qPCR reagents in a closed-tube format, the RainDrop system provides reliable results for applications requiring high accuracy in nucleic acid measurement. The RainDrop Digital PCR system found significant applications in and genetic variant detection, particularly for analyzing low-frequency tumor alleles, copy number variations, and single nucleotide polymorphisms in heterogeneous samples. For instance, it facilitated the detection of T790M mutations in formalin-fixed paraffin-embedded tissues, supporting rapid clinical assessment of resistance mutations. These capabilities enhanced non-invasive workflows and improved the sensitivity of identifying actionable genetic variants in . In January 2017, acquired RainDance Technologies for approximately $72.7 million, integrating its droplet digital PCR technologies into 's portfolio to expand offerings in life sciences and clinical diagnostics. The acquisition bolstered 's position in ultra-sensitive genomic tools for research in cancer and infectious diseases.

Ion Torrent

Ion Torrent Systems, Inc. was founded by Jonathan Rothberg in 2007 to develop semiconductor-based DNA sequencing technology that directly translates chemical changes into digital signals, bypassing optical detection methods used in prior sequencers. Rothberg served as Chairman, Chief Executive Officer, and Chief Technology Officer from 2007 to 2010. The company's flagship product, the Ion Personal Genome Machine (PGM), was launched in late 2010 as the first benchtop next-generation sequencer, enabling rapid and affordable genetic analysis with run times under two hours and costs significantly lower than traditional methods. This innovation built on Rothberg's prior work in sequencing, facilitating applications in clinical diagnostics, , and by making high-throughput sequencing accessible to smaller labs. In November 2010, (later part of ) acquired Torrent for $725 million, integrating its technology into a broader portfolio of genetic analysis tools and accelerating the adoption of chip-based sequencing platforms.

4Catalyzer

is a and manufacturing facility founded by Jonathan Rothberg in the early 2010s, designed to foster innovation at the intersection of healthcare technology, life science tools, and . Located in , the incubator provides resources, talent, and infrastructure to rapidly develop and scale medical technologies, drawing on Rothberg's experience from prior ventures such as the sale of Torrent to . Central to 4Catalyzer's model is its advanced manufacturing capabilities, particularly the use of composite materials to enable and production of devices in and diagnostics. This approach allows for the creation of , durable components that integrate semiconductors, sensors, and algorithms, accelerating the transition from concept to market-ready products. The supports a portfolio of companies, including , Hyperfine, and Quantum-Si, by providing end-to-end development services that enhance their ability to deliver transformative solutions. Through this , 4Catalyzer has raised over $2 billion in funding and contributed to global health tech impact by making advanced medical tools more affordable and accessible worldwide.

Butterfly Network

Butterfly Network, Inc. was founded in 2011 by Jonathan Rothberg with the mission to democratize through affordable, portable technology. The company pioneered ultrasound-on-a-chip technology, leveraging advancements to create compact, high-performance devices suitable for point-of-care applications worldwide. A key innovation from Butterfly Network is the Butterfly iQ, a handheld, single-probe whole-body system that connects to smartphones or tablets, enabling imaging across multiple anatomical applications without the need for multiple specialized probes. Initial prototyping and development of the iQ's chip-based architecture were supported through Rothberg's incubator, 4Catalyzer. The device utilizes capacitive micromachined ultrasonic transducers (CMUT) integrated with technology, allowing for a broad frequency range (1-10 MHz) and whole-body versatility in a probe smaller than a deck of cards. In 2018, secured $250 million in Series D funding from investors including Management and Research, valuing at $1.25 billion and enabling scaled production and commercialization of the iQ. went public in February 2021 through a SPAC merger with Longview Acquisition Corp., listing on the under the ticker BFLY at an enterprise value of approximately $1.5 billion. The Butterfly iQ received U.S. FDA clearance in 2018 for 13 clinical indications, marking the broadest approval ever for a single-probe ultrasound device and facilitating its use in diverse settings from emergency departments to remote clinics. Subsequent generations, such as the iQ+ and iQ3, have earned additional clearances for enhanced imaging modes, including AI-powered tools for automated assessments. Global adoption has accelerated point-of-care ultrasound (POCUS) integration, with over 1,000 devices deployed in Kenya and South Africa for maternal health initiatives and more than 400 units distributed in Ukraine for frontline medical use amid conflict. By 2024, Butterfly Network reported millions of scans performed across more than 100 countries, transforming diagnostics in resource-limited environments and reducing reliance on traditional cart-based systems.

Quantum-Si

Quantum-Si Incorporated is a biotechnology company focused on advancing through next-generation technology. Founded in 2013 by Jonathan Rothberg, the company aims to democratize by developing accessible tools for single-molecule analysis in and research. Building on Rothberg's expertise in from prior ventures, Quantum-Si has developed the Platinum instrument, a benchtop platform that enables real-time, single-molecule with resolution. The , commercialized in 2023, uses chip-based detection to capture fluorescent signals from N-terminal binding events, facilitating simplified workflows for and mixture sequencing. This technology supports applications in by enabling deeper insights into protein structures and modifications, such as post-translational changes, to accelerate biological research and therapeutic development. Quantum-Si went public on the exchange under the ticker QSI in June 2021 through a SPAC merger with HighCape Capital Acquisition Corp., raising capital to scale its platform. In February 2022, Rothberg assumed the role of interim CEO to guide the company's strategic direction amid leadership transitions.

Hyperfine

Hyperfine, Inc. was founded in by Jonathan Rothberg, a serial entrepreneur in biomedical innovation, with the goal of developing portable, low-field MRI systems to democratize access to by reducing costs and enabling point-of-care use. The company emerged from Rothberg's 4Catalyzer incubator, which provided early resources for prototyping advanced medical devices. Hyperfine's core technology leverages ultra-low-field magnets and AI-driven reconstruction to produce diagnostic-quality brain images without the need for shielded rooms or high-power infrastructure, addressing longstanding barriers in traditional MRI deployment. The Swoop Portable MR Imaging System, Hyperfine's flagship product, received U.S. (FDA) 510(k) clearance in September 2021 for and head in patients of all ages, marking the first portable MRI approved for clinical use. This clearance enabled the system's commercial launch, allowing deployment at the bedside to support rapid diagnosis in resource-limited environments. In December 2021, Hyperfine completed a business combination with L&F Acquisition Corp., a , and began trading on the Global Market under the HYPR. In 2025, Hyperfine advanced its technology with FDA clearance on June 2 for the next-generation Swoop system, integrated with Optive software for significantly improved image quality and ease of use, followed by the first commercial sales in July. The company reported strong business momentum in the third quarter of 2025, with preliminary revenue of $3.4 million, representing a 27% sequential increase and reflecting growing adoption of the upgraded system. To fuel expansion, Hyperfine priced a $17.5 million of in October 2025. The Swoop system has demonstrated particular value in emergency departments for streamlining and in pediatric care for accommodating young patients without sedation or transport risks, enabling clinicians to obtain critical brain images directly at the point of need. Ongoing studies, such as the PRIME launched in July 2025, are evaluating its impact on in emergency settings.

Detect

In response to the COVID-19 pandemic, Jonathan Rothberg founded Detect Inc. in 2020 to develop accessible at-home diagnostic solutions, leveraging his prior expertise in genomics and sequencing technologies from companies like Ion Torrent. The company's flagship product, the Detect COVID-19 Test, is an FDA-authorized molecular test that uses PCR-quality amplification to detect SARS-CoV-2 from self-collected nasal swabs, delivering results in about one hour without requiring laboratory processing or a prescription. Issued an Emergency Use Authorization (EUA) by the FDA on October 28, 2021, the test demonstrated high sensitivity and specificity in clinical studies, with positive percent agreement of 97.3% and negative percent agreement of 98.5% compared to standard PCR assays. Priced at around $50 per kit and supported by a reusable analyzer device, it enabled over-the-counter home use for individuals aged 2 and older, addressing key barriers to widespread testing such as convenience and cost. Detect's molecular was designed for scalability, expanding beyond single-target detection to multiplex assays capable of identifying multiple respiratory pathogens, including A/B and , from a single sample via isothermal amplification and lateral flow readouts. This capability, validated in filings and platform descriptions, allowed for comprehensive screening of common viral causes of respiratory illness, enhancing diagnostic efficiency during co-circulation of pathogens. By enabling routine, lab-independent testing, Detect significantly improved access to accurate diagnostics amid global shortages of professional testing capacity, with the U.S. selecting the company in 2021 to scale and distribute millions of kits, thereby supporting efforts to contain the pandemic. The test's home-based approach reduced reliance on overburdened healthcare facilities and empowered individuals to monitor symptoms proactively, contributing to broader epidemiological surveillance and mitigation strategies.

Identifeye Health

Identifeye Health, formerly Tesseract Health, was founded in 2018 by Jonathan Rothberg through his 4Catalyzer to advance non-invasive diagnostics via the eye. The company rebranded to Identifeye Health in to emphasize its focus on accessible retinal imaging solutions. In April 2021, it secured an oversubscribed $80 million Series B financing round led by investors including Foresite Capital and , supporting development of its core platform. The company's technology centers on retinal scans captured by a compact, app-based imaging device that produces high-quality fundus images without requiring pupil dilation or specialized training. This platform enables the diagnosis of systemic conditions like diabetes and cardiovascular disease by examining retinal biomarkers, such as microvascular changes indicative of early disease progression. Building briefly on Rothberg's prior imaging innovations at Butterfly Network and Hyperfine, Identifeye Health integrates these scans into primary care workflows to facilitate broader health screenings beyond traditional ophthalmology. At the core of its approach is AI-driven analysis, which automates image quality assessment, provides smart guidance during capture, and interprets biomarkers for early detection with high . The AI toolkit processes data to flag risks for chronic conditions, aiming to democratize preventive care in underserved settings. Identifeye Health has pursued clinical validation through pilot programs and partnerships, including collaborations with Remote Area Medical in and Dare to C.A.R.E. in to deploy its FDA-exempt screening system for in community clinics. In August 2025, the company launched its full retinal screening platform, which integrates with electronic health records and supports remote specialist review to enhance ophthalmic diagnostics efficiency. These efforts underscore its commitment to scaling AI-enabled tools for point-of-care use, with ongoing expansions into health systems for broader clinical adoption.

Liminal Sciences

Liminal Sciences, Inc. was founded in 2018 by Jonathan Rothberg as a company dedicated to advancing non-invasive monitoring technologies. The startup emerged from Rothberg's and focuses on wearable devices designed to capture real-time neurological data, simplifying access to health insights in clinical and everyday settings. At the core of Liminal's innovation is a lightweight, wearable headset that enables continuous monitoring of brain vital signs, including flow and , without invasive procedures. This technology aims to make assessments as routine as measuring , providing immediate data in intensive care units (ICUs) and extending to operating rooms (ORs), rooms (ERs), outpatient facilities, and use pending regulatory approvals. The device supports applications in monitoring by delivering accurate, real-time neurological insights to track and predict events. Liminal integrates artificial intelligence, particularly deep learning algorithms, to enhance predictive analytics from the collected data, such as forecasting seizures to allow patients to prepare or confirm periods of safety. This AI-driven approach reduces false positives and negatives in detection, offering peace of mind to individuals with epilepsy and their caregivers. The company's efforts also target sleep disorders and cognitive health, enabling ongoing evaluation of brain function in these areas through non-invasive, wearable means. Liminal's functional brain monitoring complements structural solutions like those from Rothberg's Hyperfine, together providing a more complete picture of neurological conditions. In 2021, Liminal announced plans to go public via a business combination with HealthCor Catalio Acquisition Corp. alongside Hyperfine, though the company continues to develop its technology under Rothberg's leadership.

Protein Evolution, Inc.

Protein Evolution, Inc. was founded in October 2021 by Jonathan Rothberg, a serial biotechnology entrepreneur, and Connor Lynn, a Yale University alumnus with expertise in enzyme engineering. The company emerged from stealth mode in November 2022, securing approximately $25 million in an initial venture funding round led by investors including Collab Fund and New Climate Ventures. This capital supported the development of its core technology and early demonstrations of enzyme applications. The company's platform integrates tools, such as physics-informed language models and AlphaFold-inspired structure prediction, with and to design and optimize novel enzymes and proteins. This approach enables rapid iteration, compressing millions of years of natural evolutionary processes into weeks by generating diverse protein libraries, screening for desired traits like enhanced stability or activity, and refining candidates through . Drawing briefly from Rothberg's prior work in at Quantum-Si, the platform emphasizes functional validation to deliver lab-ready sequences for challenging tasks. Protein Evolution's technology holds potential applications in therapeutics, where directed evolution can enhance protein drugs for better efficacy, stability, or specificity in treating diseases, and in industrial biotechnology, particularly for sustainable processes like enzymatic of plastics and textiles. For instance, the platform has produced enzymes capable of depolymerizing waste into reusable monomers, enabling infinite and reducing reliance on virgin petroleum-based materials in .

Personal life

Family

Jonathan Rothberg is married to Bonnie Rothberg, a who holds a PhD in epidemiology from . The couple has five children. Rothberg resides in Miami, Florida, to which he relocated in 2021 from , where he retains strong ties through property ownership. In , he owns a 13.3-acre waterfront estate featuring a replica of ; the property was listed for sale in 2024 for $35 million. Additionally, the family owns Chamard Vineyards, a 40-acre property in , which Rothberg acquired in 2005 out of interest in ; it was listed for sale in 2024 for $8.5 million. As of 2025, Rothberg owns the superyacht Gene Machine, a 55-meter Amels vessel equipped with a , on which he and his family spend extended periods, particularly summers. In May 2024, a smaller boat owned by Rothberg was involved in a fatal accident off , in which 15-year-old Ella Adler was struck and killed by another vessel while being towed; Rothberg was not aboard the boat.

Philanthropy and interests

In 2002, Jonathan Rothberg and his wife, Bonnie, founded the Rothberg Institute for Childhood Diseases, a nonprofit organization dedicated to advancing research and developing treatments for tuberous sclerosis complex (TSC), a rare genetic disorder that affects one of their children. The institute focuses on discovering novel chemical and biological therapies, collaborating with partners like the TSC Alliance to accelerate drug discovery efforts specific to TSC. Through the Rothberg Family Charitable Foundation for Children's Diseases, Rothberg supports broader biomedical research initiatives aimed at addressing pediatric conditions, including contributions to preclinical studies and clinical advancements in rare diseases. Beyond , Rothberg pursues personal interests in and . An avid sailor, he owns the Gene Machine, a vessel equipped with onboard laboratories that facilitates scientific research and exploration at sea, blending his passion for maritime adventure with opportunities for innovation. He also owns Chamard Vineyards in , acquired in 2005, where he engages in and wine production, cultivating varietals on the estate's 20 acres to produce around 6,000 cases annually. Rothberg's charitable efforts extend to commitments promoting access, particularly in underserved areas, by funding initiatives that enhance diagnostic and therapeutic resources for rare and childhood diseases worldwide.

Recognition

Awards

Jonathan Rothberg has received several prestigious awards recognizing his contributions to and scientific innovation, particularly in and . He was named a Technology Pioneer four times: in 2002 for CuraGen Corporation, in 2007 for 454 Life Sciences, in 2008 for RainDance Technologies, and in 2015 for . In 2001, Rothberg received the Entrepreneur of the Year award. In 2016, Rothberg was awarded the National Medal of Technology and Innovation by President , the highest honor for technological achievement in the United States, for his pioneering inventions and commercialization of next-generation technologies. The Connecticut Medal of Technology was bestowed upon Rothberg in 2010 by the Connecticut Academy of Science and , honoring his leadership in advancing and as the founder and CEO of Ion Torrent. In 2012, Graduate School of Arts and Sciences presented Rothberg with the Wilbur Cross Medal, its highest alumni honor, acknowledging his distinguished achievements in applying principles to and . Rothberg received the Award for Excellence in from the Association for Molecular Pathology in 2018, recognizing his transformative impact on diagnostic technologies through innovations in high-throughput sequencing. In 2023, Rothberg was inducted into the Florida Inventors Hall of Fame for pioneering next-generation human technologies that enable low-cost decoding of human and other living organisms' genomes.

Professional affiliations

Jonathan Rothberg was elected to the in 2004 for his contributions to the application of engineering principles in genomic information processing. He is also a member of the Connecticut Academy of Science and Engineering, elected in 2005, which promotes advancements in science and technology with a focus on innovation. Rothberg holds ongoing board positions at several and companies as of 2025. He serves as an and chair of the Nominating & Corporate Governance Committee at , Inc., a role he has maintained since founding the company in 2014. At Hyperfine, Inc., he has been a director since 2014, following his founding of the company to advance portable MRI technology. Additionally, Rothberg remains a director at Quantum-Si Incorporated, where he founded the company in 2013 and previously served as chairman until 2024. In academic affiliations, Rothberg serves as an of research in at , a position he has held since 2015, supporting at the intersection of and . He is also a life trustee at , contributing to strategic oversight in and programs.

References

  1. [1]
    About - Jonathan Rothberg
    He was awarded the National Medal of Technology and Innovation, the nation's highest honor for technological achievement, by President Obama for inventing and ...
  2. [2]
    Jonathan Rothberg, PhD - Yale School of Medicine
    May 13, 2024 · Dr. Jonathan Rothberg is best known for inventing high-speed, “Next-Gen” DNA sequencing. He founded 454 Life Sciences.
  3. [3]
    Renowned biomedical entrepreneur helps drive innovation at ...
    Jul 5, 2023 · Born in 1963 in New Haven, Connecticut, to a family of entrepreneurs, Rothberg earned a B.S. in chemical engineering from Carnegie Mellon and an ...Missing: biography | Show results with:biography
  4. [4]
    2013 Laureates - National Medal of Technology and Innovation
    Oct 17, 2016 · Jonathan Rothberg. Jonathan Marc Rothberg 4catalyzer Corporation and Yale School of Medicine. For pioneering inventions and commercialization ...
  5. [5]
    Jonathan Rothberg's Race to Invent the Ultimate Rapid At-Home ...
    Aug 29, 2020 · Rothberg was born in Connecticut, the second-youngest of seven siblings. His father, Henry Rothberg, had made a small fortune with the invention ...
  6. [6]
    2022 Innovator: Jonathan Rothberg is CT's most prolific innovator
    Dec 5, 2022 · Rothberg was awarded the National Medal of Technology and Innovation by President Barack Obama in 2016. He is a member of the National Academy ...Missing: biography achievements<|control11|><|separator|>
  7. [7]
    He Did It | Carnegie Mellon Today
    Jan 2, 2012 · He often went on sales calls as a boy with his dad, Henry Rothberg, who founded Laticrete International, which makes adhesives for stone and ...
  8. [8]
    Alumni Profile: Jonathan Rothberg (GSAS '91)
    May 12, 2023 · While still working at Curagen, Rothberg founded his second company, 454 Life Sciences, to develop this revolutionary technology. Rothberg's ...<|control11|><|separator|>
  9. [9]
    Renowned scientist owns boat towing girl killed off Key Biscayne
    May 22, 2024 · In 2021, Rothberg moved to South Florida from Connecticut, buying a $23.5 million house off the Venetian Causeway, Miami-Dade property records ...Missing: residence | Show results with:residence
  10. [10]
    CMU Alumnus, Trustee Jonathan Rothberg To Receive National ...
    Dec 23, 2015 · Rothberg, a 1985 CMU engineering graduate, is founder of a string of successful companies, including 454 Life Science, CuraGen, Ion Torrent, ...
  11. [11]
    A History of Innovation at Yale
    His thesis work centered on decoding the slit gene which is responsible for the wiring of the nervous system. Rothberg founded CuraGen while at Yale, one of the ...
  12. [12]
    Jonathan M. Rothberg
    When his son Noah was born in 1999 and rushed, not breathing, to newborn intensive care, Jonathan realized he wanted to develop drugs based on personal genomes.Missing: family background
  13. [13]
    The development and impact of 454 sequencing - Nature Biotechnology
    ### Summary of 454 Sequencing (Nature Biotechnology, https://www.nature.com/articles/nbt1485)
  14. [14]
    The complete genome of an individual by massively parallel DNA ...
    Apr 17, 2008 · Here we report the DNA sequence of a diploid genome of a single individual, James D. Watson, sequenced to 7.4-fold redundancy in two months ...Online Methods · Dna Sequencing · Genotyping With Sequence...
  15. [15]
    In His Genes: Jonathan Rothberg - Yachts International
    Sep 23, 2022 · Scientist, inventor, entrepreneur, and founder of CuraGen, Jonathan Rothberg toggles between two superyachts: one which serves as a high-tech lab for work, and ...Missing: early background
  16. [16]
    https://pmc.ncbi.nlm.nih.gov/articles/PMC2771884/
  17. [17]
    High-Throughput Quantitative PCR in Picoliter Droplets - PMC
    We have designed a high-throughput microfluidic chip that encapsulates PCR reagents in millions of picoliter droplets in a continuous oil flow.<|separator|>
  18. [18]
    Real-time dynamic single-molecule protein sequencing on ... - Science
    Oct 13, 2022 · Here, we demonstrate single-molecule protein sequencing using a dynamic approach in which single peptides are probed in real time by a mixture ...
  19. [19]
    Giving everyone a window into the human body | MIT News
    Feb 6, 2018 · Butterfly Network, a startup co-founded by an MIT alumnus, aims to make ultrasound imaging as simple and ubiquitous as blood-pressure or ...
  20. [20]
    A serial entrepreneur wants his portable MRI to transform medicine
    Oct 25, 2019 · Hyperfine says the unit is 20 times less costly to build, 10 times lighter, and uses 35 times less power than a 1.5 Tesla MRI.
  21. [21]
    https://pubmed.ncbi.nlm.nih.gov/12164777/
  22. [22]
    CuraGen Corporation - PubMed
    One important application of functional genomics is in the area of pharmacogenomics, which has been a critical component in CuraGen's drug discovery and ...Missing: focus | Show results with:focus
  23. [23]
    Venture-funded Firms: Data from Hoover's Small Business Database ...
    CuraGen Corporation, 26,790.0, 2, 9/1/1999, 3/1/1997, NASDAQ, CRGN, 39.6, 666, (59.8). CytoLogix Corporation, 46,850.0, 5, 5/29/2002, 1/1/1997, private.<|separator|>
  24. [24]
    Press Release - SEC.gov
    CuraGen Corporation (NASDAQ: CRGN) announced today that Jonathan M. Rothberg, Ph.D. has informed the Board of Directors of his intention to step down.Missing: merger dissolution
  25. [25]
    CuraGen CEO Rothberg to step down - BioCentury
    Apr 6, 2005 · CRGN said CEO Jonathan Rothberg will step down after the company appoints a new CEO. Rothberg founded CRGN in 1993. The company has two ...Missing: IPO merger dissolution
  26. [26]
    Celldex acquires CuraGen for $94.5M - Fierce Biotech
    May 29, 2009 · Massachusetts-based Celldex Therapeutics is paying $94.5 million to acquire CuraGen. Celldex gains CuraGen's portfolio of 11 oncology-focused antibodies.
  27. [27]
    Rothberg Returns: Quantum-Si Aims to Turn Proteomics Digital
    Jun 17, 2021 · Jonathan Rothberg, PhD, tells GEN ... research and drug discovery through an enhanced version of the sequencing technology he invented.<|control11|><|separator|>
  28. [28]
    454 Life Sciences Installs Twenty GS20 Systems In The First Year Of ...
    Jan 12, 2006 · Beginning in October 2005, the Genome System 20 System and reagents have been distributed worldwide by Roche Applied Science, a business unit of ...
  29. [29]
    454 Life Sciences: Illuminating the future of genome sequencing ...
    As the story goes, 454's founder Jonathan Rothberg, PhD, was faced with a family health emergency. His newborn son was ill, and as he waited to hear news ...
  30. [30]
    Roche Buys 454 for $154.9M
    Mar 29, 2007 · Roche will acquire 454 Life Sciences from Curagen in a transaction worth $154.9 million. Roche will pay $140 million in cash.
  31. [31]
    Six Years After Acquisition, Roche Quietly Shutters 454 - Bio-IT World
    Oct 16, 2013 · The same year, 454 released the first commercially available next-generation sequencer, the GS20, and began its relationship with Roche with a ...
  32. [32]
    The history of sequencing DNA - ScienceDirect
    Pyrosequencing was later licensed to 454 Life Sciences, a biotechnology company founded by Jonathan Rothburg, where it evolved into the first major ...
  33. [33]
    Jonathan Rothberg, Ph.D. - Board Member - Quantum-Si Incorporated
    Dr. Rothberg is a scientist and entrepreneur who was awarded the National Medal of Technology and Innovation, the nation's highest honor for technological ...
  34. [34]
    RainDance Technologies | RainDrop Digital PCR
    Capable of generating more than a billion reactions in a single day, the new RainDrop™ Digital PCR System from RainDance Technologies establishes a new ...Company Overview · RainDrop™ Digital PCR · RainDrop Content
  35. [35]
    [PDF] Quantitative digital PCR analysis of cancer gene promoter ...
    RainDance Technologies' RainDrop™ dPCR system is a highly sensitive tool for precise quantification of nucleic acids using probe-based qPCR reagents ...<|control11|><|separator|>
  36. [36]
    Clinical Application of Picodroplet Digital PCR Technology for Rapid ...
    Rapid testing for T790M was performed using the Raindrop dPCR ... Determining lower limits of detection of digital PCR assays for cancer-related gene mutations.
  37. [37]
    Bio-Rad To Acquire RainDance Technologies and Droplet ...
    Jan 15, 2017 · The terms of the acquisition were not disclosed. Bio-Rad expects the transaction to close during the first quarter of 2017. The company will ...
  38. [38]
    Untitled
    In February 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately $72.7 million.
  39. [39]
    4Catalyzer Corporation - BioCT
    530 Old Whitfield Street Guilford, CT 06437. Phone: 203-458-7100. Website: https://4Catalyzer.com. General Information: At 4Catalyzer we are transforming ...
  40. [40]
    Yale entrepreneur Rothberg rounds up $40M for a biotech upstart
    Feb 3, 2016 · Rothberg founded 4Catalyzer after selling 454 to Roche ($RHHBY) and Ion Torrent to Life Technologies. The incubator's most advanced company ...
  41. [41]
    About 4 Catalyzer
    Our Startups have built the world's first full-body ultrasound on a semiconductor chip (Butterfly Network), commercialized the first FDA approved portable MRI ...Missing: advanced composites imaging diagnostics
  42. [42]
    https://www.fiercebiotech.com/r-d/yale-entrepreneur-rothberg-rounds-up-40m-for-a-biotech-upstart
  43. [43]
    NYSE: BFLY - 4 Catalyzer 2019
    Butterfly Network is the world's first handheld whole-body scanner on a semiconductor chip. $2,399, enabled by ultrasound-on-a-chip technology ...Missing: prototyping | Show results with:prototyping
  44. [44]
    Aiming To Revolutionize Medical Ultrasound, Butterfly Raises $250 ...
    Sep 28, 2018 · Butterfly Network, the maker of a $2,000 handheld ultrasound device, has raised $250 million from large private investors.
  45. [45]
    https://www.4catalyzer.com/our-companies/butterfly-network
  46. [46]
    https://www.forbes.com/sites/matthewherper/2018/09/27/aiming-to-revolutionize-medical-ultrasound-butterfly-raises-250-million-at-a-125-billion-valuation/
  47. [47]
    https://www.butterflynetwork.com/press-releases/butterfly-network-closes-business-combination-and-will-begin-trading-on-the-nyse
  48. [48]
    Butterfly Network and Razom Expand Global Health Partnership To ...
    Oct 4, 2023 · Razom has now alone deployed over 400 Butterfly iQ+ devices to Ukraine, and has been a leader in driving Point-of-Care Ultrasound (POCUS) ...
  49. [49]
    https://www.butterflynetwork.com/case-studies-1000-probes
  50. [50]
    About - Quantum-Si
    Jonathan Rothberg founded Quantum-Si in 2013 to make protein sequencing accessible to the proteomics and multiomics community.Careers · Leadership · Customer Connections
  51. [51]
    Quantum-Si, a Pioneer in Semiconductor Chip-Based
    Feb 18, 2021 · Jonathan Rothberg, to become Executive Chairman of the combined company and will be joined on its board of directors by Kevin Rakin, Chief ...
  52. [52]
    Quantum-Si Commercializes the First Single-Molecule Protein NGS ...
    Jan 3, 2023 · Quantum-Si Incorporated (QSI) has unveiled Platinum, the first platform for single-molecule protein sequencing of the next generation.
  53. [53]
    Platinum™ Proteomics Platform - Quantum-Si
    Platinum is a benchtop platform for protein sequencing, offering a simple workflow, end-to-end solution, and single-molecule amino acid resolution.Missing: development | Show results with:development
  54. [54]
    Next-Generation Protein Sequencing Technology - Quantum-Si
    Platinum® Pro sequences peptides by capturing fluorescent signals from each N-terminal amino acid (NAA) binding event, enabling real-time, single-molecule ...<|control11|><|separator|>
  55. [55]
    Quantum-Si Launches Platinum® Pro: The End-to-End Solution for ...
    Jan 13, 2025 · Platinum Pro delivers a comprehensive solution for sequencing and analyzing proteins in a simple, integrated workflow. Its design prioritizes ...
  56. [56]
    Branford-based biotech Quantum-Si eyes $50M capital raise
    Jan 6, 2025 · Founded by serial scientist-entrepreneur Jonathan Rothberg to commercialize protein-sequencing technology, Quantum-Si went public in June 2021, ...Missing: CEO | Show results with:CEO
  57. [57]
    Quantum-Si Announces Dr. Jonathan Rothberg as Interim CEO
    Feb 14, 2022 · Dr. Jonathan Rothberg, Founder and Executive Chairman, is the Interim CEO of Quantum-Si, succeeding John Stark, effective February 8, 2022.
  58. [58]
    Hyperfine, Inc., creator of the first FDA-cleared portable MRI device ...
    Jul 8, 2021 · Hyperfine was founded in 2014 by Dr. Jonathan Rothberg, a serial entrepreneur who received the Presidential Medal of Technology & Innovation ...
  59. [59]
    4 Catalyzer 2019
    Hyperfine has built the world's first affordable, Point-of-Care MRI device that costs a fraction of traditional MRI and plugs into a wall outlet.Missing: advanced composites diagnostics
  60. [60]
    About Hyperfine
    Hyperfine was founded in 2014 by Jonathan Rothberg, PhD, a serial ... MRI technology over 40 years ago. Hyperfine produced the first Swoop system MR ...
  61. [61]
    Hyperfine Receives FDA Clearance for Deep Learning Portable MRI ...
    Nov 29, 2021 · World's first portable MRI transforms imaging at the patient's bedside with deep learning to enable timely diagnosis and treatment.
  62. [62]
    Hyperfine closes SPAC merger, will begin trading on Nasdaq
    Dec 22, 2021 · Hyperfine's Class A common stock will begin trading on the Nasdaq global market on December 23, 2021, under the symbol “HYPR.” “Our public ...
  63. [63]
    Hyperfine Announces FDA Clearance of a New Next-Generation ...
    Jun 2, 2025 · The Swoop® Portable MR Imaging® (V2) System is U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. It ...Missing: 2021 | Show results with:2021
  64. [64]
    Hyperfine Announces the First Commercial Sales of the Next ...
    Jul 17, 2025 · The Swoop® Portable MR Imaging® (V2) System is U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. It ...Missing: 2021 | Show results with:2021<|separator|>
  65. [65]
    Hyperfine Reports Preliminary, Unaudited Results for Third Quarter ...
    ... Launch of the Next Generation Swoop® System. Oct 15, 2025. |. PDF Version. GUILFORD, Conn. --(BUSINESS WIRE)--Oct. 15, 2025-- Hyperfine, Inc. (Nasdaq: ...
  66. [66]
    Hyperfine Announces Pricing of $17.5 Million Public Offering
    The gross proceeds to Hyperfine from the offering are expected to be approximately $17.5 million , before deducting underwriting discounts and commissions and ...
  67. [67]
    Portable MRI for Hospitals | Bedside Brain Imaging - Hyperfine
    Enable bedside brain imaging in the ICU and ED with the Swoop® system—a portable, cost-effective MRI solution that improves care, speeds diagnosis, ...
  68. [68]
    Hyperfine's Swoop Portable MRI System - Medical Device Network
    Jun 21, 2024 · Swoop received 510(k) clearance from the US Food and Drug Administration (FDA) for MRI of the brain and head of patients of all ages, including ...
  69. [69]
    Hyperfine Announces First Patients Enrolled in PRIME Study Aimed ...
    Jul 31, 2025 · The real-world study will assess the clinical and operational impact of portable MRI across diverse patient types in ED settings.Missing: applications | Show results with:applications
  70. [70]
    Client Spotlight on Detect - Wolf Greenfield
    Rothberg founded Detect™, and the Connecticut-based company developed a revolutionary molecular self-administrable test that provides PCR-quality Covid-19 test ...
  71. [71]
    [PDF] Detect Covid-19 Test - Letter of Authorization - FDA
    Apr 11, 2022 · The Detect Covid-19 Test is for home use, detecting SARS-CoV-2 via nasal swabs. It can be used for those suspected of COVID-19, or twice in 3 ...
  72. [72]
    Detect™ Covid-19 Test Receives FDA Emergency Use ... - Nasdaq
    Oct 29, 2021 · Detect™ Covid-19 Test Receives FDA Emergency Use Authorization for Over-the-Counter Home Use. Published. Oct 29, 2021 9:13am EDT. PCR-Quality ...<|control11|><|separator|>
  73. [73]
    [PDF] Detect Covid-19 Test - Healthcare Provider Fact Sheet - FDA
    The Detect Covid-19 Test is authorized for non- prescription home use with adult-collected anterior nasal swab samples from individuals aged 2 years or older ...
  74. [74]
    Detect's PCR-Quality At-Home Rapid Covid-19 Test Now Available ...
    Dec 15, 2021 · Detect's FDA authorized PCR-quality rapid Covid-19 test requires only three minutes of hands-on time to provide accurate PCR-quality results at home in one ...
  75. [75]
    Detect nets FDA green light to bring routine molecular COVID testing ...
    Nov 1, 2021 · Equipped with a reusable analyzer and $50 cartridge-based tests, the system aims to produce results with PCR-level accuracy within one hour.
  76. [76]
    US20210292825A1 - Rapid diagnostic test - Google Patents
    ... Detect test with the listed respiratory pathogens, including other coronaviruses. ... Multiplex PCR primer and probe combination for detecting 18 pathogens ...
  77. [77]
    Sell or Invest in Detect Stock Pre-IPO | 1% Fee on Trades
    Their molecular platform provides multiplex testing from a single sample at ... Detect Management Team. Founder. Jonathan Rothberg. Learn More About ...
  78. [78]
    Detect™ Selected by NIH to Scale Manufacturing of PCR-Quality ...
    Oct 14, 2021 · Jonathan Rothberg, Detect Inc. has created an accurate, fast, and easy-to-use PCR-quality molecular Covid-19 test. The technology also ...
  79. [79]
    [2020-12-23] Murphy Highlights Connecticut Innovator Detect As...
    “The Detect COVID-19 test combines the accuracy of a PCR test with the speed and simplicity of an antigen test, without needing a lab or a prescription.
  80. [80]
    How to test everyone for the coronavirus - MIT Technology Review
    Apr 16, 2020 · Rothberg's is one of several attempts to create a test that's simple, foolproof, and cheap enough for anyone to do at home.
  81. [81]
    Bringing Routine Covid-19 Testing Into The Home - Forbes
    Dec 20, 2020 · Detect is working on making more accurate routine Covid-19 testing a reality. The company uses novel molecular technology to bring both speed and accuracy.Missing: launch | Show results with:launch
  82. [82]
    Tesseract Health Closes Oversubscribed $80 Million Series B ...
    Apr 20, 2021 · “Our mission is to democratize healthcare on a global scale,” commented company founder, Dr. Jonathan Rothberg. “Tesseract aims to disrupt ...<|control11|><|separator|>
  83. [83]
    identifeye HEALTH Launches AI-Powered Retinal Imaging System
    Oct 18, 2024 · ... rebranded Tesseract to identifeye HEALTH. She is now leading the charge to democratize access to retinal imaging, leveraging AI and ...
  84. [84]
    identifeye HEALTH launches retinal screening platform
    Aug 26, 2025 · The identifeye HEALTH platform incorporates automated features to streamline workflow, image capture, and quality assessment, while clinical ...
  85. [85]
    Retinal Screening Reimagined - identifeye HEALTH - Frog Design
    identifeye HEALTH is working to harness insights from human eyes, using a highly automated retinal imaging platform and advanced AI to promote overall healthMissing: scans clinical trials
  86. [86]
    Identifeye hopes retinal imaging will be a window into health
    Sep 9, 2025 · Led by a founding member of Google Life Sciences, Identifeye Health believes noninvasive retinal scans will reveal much more in the future.
  87. [87]
    identifeye HEALTH Platform
    Our end-to-end platform combines the identifeye Camera and Portal to deliver simple, streamlined fundus imaging workflows in point-of-care settings.
  88. [88]
    Identifeye HEALTH Launches AI-Powered Retinal Screening ...
    Aug 20, 2025 · Designed to bring screenings closer to patients, the solution streamlines workflow, reduces barriers to care, and enhances clinical efficiency.
  89. [89]
    identifeye HEALTH Launches FDA-Exempt Retinal Screening ...
    Aug 20, 2025 · With its commercial rollout, identifeye HEALTH is delivering retinal screening results directly to patients and partnering with health systems, ...Missing: trials | Show results with:trials
  90. [90]
    Identifeye Working To Put Automated Diabetic Retinopathy ...
    Oct 18, 2024 · Medtech Insight spoke with Vicky Demas, CEO of Identifeye, about plans for bringing the company's AI-powered retinal screening system for ...<|control11|><|separator|>
  91. [91]
    http://www.mobilehealthtimes.com/identifeye-health-launches-fda-exempt-retinal-screening-platform-expands-access-to-vision-saving-care/
  92. [92]
    Mintz Advises Med-Tech Start-Ups Hyperfine and Liminal in $580 ...
    Jul 12, 2021 · Founded by scientist and serial entrepreneur Dr. Jonathan Rothberg, Hyperfine is an innovative medical technology business with a mission to ...
  93. [93]
    Liminal Sciences by Brûlée Studio
    With deep learning, we are pushing the boundaries of seizure prediction—so patients can prepare for an event, or know when they are in the clear.
  94. [94]
    This Startup's AI Designs Enzymes That Can Eat Plastic Waste
    May 3, 2024 · Serial inventor Jonathan Rothberg's Protein Evolution found a solution: using AI to create enzymes that can recycle old polyester textiles into a material that ...Missing: 2022 biotech
  95. [95]
    Protein Evolution Recycles Plastics Quickly - "1 Million Years Of ...
    Nov 1, 2022 · The company was founded in 2021 by Yale University alumni Connor Lynn and Scott Stankey, in partnership with Dr. Jonathan Rothberg, a world ...Missing: $25 | Show results with:$25
  96. [96]
    Client Spotlight on Protein Evolution - Wolf Greenfield
    The company was founded in 2021 by entrepreneur Connor Lynn in partnership with Jonathan Rothberg, Ph.D., a world-renowned scientist, entrepreneur and ...Missing: platform screening therapeutics
  97. [97]
    Protein Evolution Engineers Supercharged Organisms To Break ...
    Oct 31, 2022 · The company is coming out of stealth mode today, announcing its technology and initial funding of more than $2o million. “We use artificial ...Missing: therapeutics | Show results with:therapeutics
  98. [98]
    Protein Evolution
    Protein evolution uses AI to improve existing enzymes, discover novel ones, and rescue stalled programs, preserving activity while enabling large-scale ...
  99. [99]
    [PDF] QUANTUM-SI INCORPORATED
    The net cash used in operating activities of $24.3 million for ... Agreement (“TSEA”) between Quantum-Si Incorporated (“Q-Si”) and Protein Evolution, Inc.
  100. [100]
    Protein Evolution, Inc. Unveils New Technology that Infinitely ...
    Oct 31, 2022 · Emerging from stealth with over $20M in funding, the company is poised to usher in a new era of truly sustainable and circular plastics.Missing: $25 | Show results with:$25
  101. [101]
    Guess the price of Jonathan Rothberg's waterfront estate in Guilford
    Jul 30, 2024 · The most expensive piece of real estate on the mainland shoreline, a 13.3 acre waterfront estate, is on the market for $35 million.Missing: Florida | Show results with:Florida
  102. [102]
    Guilford Stone House Restaurant property for sale at $4.25 M
    Mar 9, 2024 · Along with two other pieces of Guilford property, the Rothberg family is selling the 40-acre Chamard Vineyard in Clinton, listed at $8.5 million ...
  103. [103]
    On board with Jonathan Rothberg, owner of 55m explorer yacht ...
    Nov 25, 2021 · Accomplished DNA sequencing scientist, Dr Jonathan Rothberg, owner of 55m Gene Machine and support vessel Gene Chaser discusses the next stage of his journey.
  104. [104]
    Rothberg Institute For Childhood Diseases
    A non-profit research institution devoted to discovering, developing and commercializing novel chemical and biological entities for the treatment of tuberous ...
  105. [105]
    Spotlight on TSC Alliance
    TS Alliance announces partnership with The Rothberg Institute for Childhood Diseases to advance drug discovery efforts specific to TSC. TS Alliance awards ...
  106. [106]
    Rothberg Fam Charitable Foundation for Childrens Diseases
    Profile for Rothberg Fam Charitable Foundation for Childrens Diseases (Miami Beach, FL - EIN 061519674) including grantees and board members as of 2023 tax ...Missing: biomedical | Show results with:biomedical
  107. [107]
    Preclinical research - TSC Alliance
    Bonnie and Jonathan Rothberg & Family, and many additional donors through the Unlock the Cure campaign. Company Members also support the Consortium through ...
  108. [108]
    Business Profile: Chamard Vineyards | Clinton, CT Patch
    May 3, 2011 · Dr. Jonathan M. Rothberg has owned Chamard Vineyards since the fall of 2005, a property originally incorporated by the former Chairman and CEO of Tiffany & Co.
  109. [109]
    Chamard Vineyards - Connecticut (CT) Wine Trail
    40 Acres; 20 cultivated. Annual Produced Cases: 5,000. Owners: Drs. Jonathan and Bonnie Rothberg. Winemakers: Kristen Parsons & Ray Ambrose. No Outside Food ...
  110. [110]
    Jonathan Marc Rothberg
    Birthday: January 1, 1963; Age Awarded: 50; Awarded By: Barack Obama; Country: USA; Key Contributions: Massively Parallel DNA Sequencing; Education: Yale ...Missing: 28 source
  111. [111]
    President Obama Honors Nation's Leading Scientists and Innovators
    May 19, 2016 · The President will award the National Medal of Science and the National Medal of Technology and Innovation in the East Room of the White House.
  112. [112]
    Genetics Entrepreneur Jonathan Rothberg Wins CT Medal of ...
    PRNewswire/ -- Dr. Jonathan M. Rothberg, chairman, CEO and founder of Guilford-based Ion Torrent, has been named the 2010 winner of the Connecticut Medal of ...
  113. [113]
    Yale University Graduate School to honor four alumni
    Oct 5, 2012 · Four distinguished alumni of the Yale Graduate School of Arts and Sciences will be awarded Wilbur Lucius Cross Medals, the school's highest ...
  114. [114]
    Past Recipients - Association for Molecular Pathology
    Award for Excellence in Molecular Diagnostics Past Recipients ; 2018, Jonathan Rothberg, PhD ; 2017, Andrew P. Feinberg, MD, MPH ; 2016, Eric Lander, PhD ; 2015 ...
  115. [115]
    Jonathan Rothberg Ph.D. - Butterfly Network, Inc. - Investor Relations
    Dr. Rothberg is a scientist and entrepreneur who was awarded the National Medal of Technology and Innovation, the nation's highest honor for technological ...Missing: biography | Show results with:biography
  116. [116]
    Jonathan Rothberg, | Board Member - Hyperfine, Inc.
    Dr. Rothberg is a scientist and entrepreneur who was awarded the National Medal of Technology and Innovation, the nation's highest honor for technological ...